Skip to main content
SpringerLink
Log in

Marker für minimale Resterkrankung: Minimal Residual Disease

  • Living reference work entry
  • First Online:
Kompendium Internistische Onkologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 29 Accesses

Zusammenfassung

In den letzten Jahren wurden wesentliche Fortschritte im biologischen Verständnis und der Therapie von hämatologischen Neoplasien und soliden Tumoren erzielt. Durch den Einsatz innovativer Therapiekonzepte erreichen mittlerweile viele Patienten komplette Remissionen ihrer Erkrankung. Dennoch verbleiben auch in der Phase der klinischen Remission oftmals residuelle Tumorzellen im Körper des Patienten, die die sogenannte „minimal residual disease“ (MRD) ausmachen und den Ausgangspunkt für ein klinisches Rezidiv darstellen. Deshalb hat die MRD-Quantifizierung im Therapieverlauf vor allem bei hämatologischen Neoplasien eine erhebliche prognostische Bedeutung gewonnen und Eingang in die Therapiestratifikation insbesondere bei der ALL, AML und CML gefunden. Bei soliden Tumoren beschränken sich die meisten Studien auf den Nachweis und die Charakterisierung von zirkulierenden Tumorzellen bzw. zirkulierender Tumor-DNA/-RNA bei Diagnosestellung oder im Rezidiv. Allerdings zeigt sich zunehmend, dass auch für diese Tumorerkrankungen eine Charakterisierung persistierender Tumorzellen in der Phase der klinischen Remission relevante Einblicke in die Biologie der Erkrankung und des metastatischen Prozesses sowie die Prognose des Patienten erlaubt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Literatur

  • Baccarani M, Deininger MW, Rosti G et al (2013) Review Article European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872–884

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bader P, Salzmann-Manrique E, Balduzzi A et al (2019) More precicely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Adv 3(21):3393–3405

    Article  PubMed  PubMed Central  Google Scholar 

  • Berry DA, Zhou S, Higley H et al (2017) Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia. JAMA Oncol 3(7):e170580

    Article  PubMed  PubMed Central  Google Scholar 

  • Böttcher S, Ritgen M, Fischer K et al (2012) Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 30(9):980–988

    Article  PubMed  Google Scholar 

  • Brüggemann M, Raff T, Flohr T et al (2006) Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 107(3):1116–1123

    Article  PubMed  Google Scholar 

  • Brüggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, Asnafi V, Baruchel A, Bassan R, Benoit Y, Biondi A, Cavé H, Dombret H, Fielding AK, Foà R, Gökbuget N, Goldstone AH, Goulden N, Henze G, Hoelzer D, Janka-Schaub GE, Macintyre EA, Pieters R, Rambaldi A, Ribera JM, Schmiegelow K, Spinelli O, Stary J, von Stackelberg A, Kneba M, Schrappe M, van Dongen JJM, also on behalf of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) (2010) Standardized MRD quantification in European ALL Trials: proceedings of the second international symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 24:521–535

    Article  PubMed  Google Scholar 

  • Byrd JC, Brown JR, O’Brien S et al (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371(3):213–223

    Article  PubMed  PubMed Central  Google Scholar 

  • Debarri H, Lebon D, Roumier C et al (2015) IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget 6(39):42345–42353

    Article  PubMed  PubMed Central  Google Scholar 

  • Dongen JJM van, van der Velden VH, Brüggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood 2015;125(26):3996-4009

    Google Scholar 

  • Evans PAS, Pott Ch, Groenen PJTA et al (2007) Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 21(2):207–214

    Google Scholar 

  • Freeman SD, Virgo P, Couzens S et al (2013) Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 31(32):4123–4131

    Article  PubMed  Google Scholar 

  • Gökbuget N, Kneba M, Raff T et al (2012) Adult patients with acute lymphoblastic leukemia ans molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 120(9):1868–1876

    Article  PubMed  Google Scholar 

  • Gökbuget M, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, Bargou RC (2018) Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia. Blood blood-2017-08-798322; published ahead of print January 22, 2018. https://doi.org/10.1182/blood-2017-08-798322

  • Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel Y, Flora R, Diverio D, Jones K, Aslett H, Batson E, Rennie K, Angell R, Clark RE, Solomon E, Lo-Coco F, Wheatley K, Burnett AK (2009) Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 27(22):3650–3658

    Article  CAS  PubMed  Google Scholar 

  • Hallek M, Cheson BD, Catovsky D et al (2018) Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. Blood 131(25):blood-2017-09-806398

    Google Scholar 

  • Ivey A, Hills RK, Simpson MA et al (2016) Assessment of minimal residual disease in standard-risk AML. N Engl J Med 374(5):422–433

    Article  CAS  PubMed  Google Scholar 

  • Kovacs G, Robrecht S, Fink AM et al (2016) Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group. J Clin Oncol 34(31):3758–3765

    Article  CAS  PubMed  Google Scholar 

  • Kumar S, Paiva B, Anderson KC et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328–e346

    Article  PubMed  Google Scholar 

  • Ladetto M, De Marco F, Benedetti F et al (2008) Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival. Blood 111(8):4004–4013

    Article  CAS  PubMed  Google Scholar 

  • Ladetto M, Lobetti-bodoni C, Mantoan B et al (2013) Persistence of minimal residual disease in the bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood 122(23):3759–3766

    Article  CAS  PubMed  Google Scholar 

  • Lahuerta JJ, Paiva B, Vidriales MB et al (2017) Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials. J Clin Oncol 35(25):2900–2910

    Article  CAS  PubMed  Google Scholar 

  • Leich E, Ott G, Rosenwald A (2011) Pathology, pathogenesis and molecular genetics of follicular NHL. Best Pract Res Clin Haematol 24(2):95–109

    Article  CAS  PubMed  Google Scholar 

  • Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D’Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F (2017) Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 Trial. J Clin Oncol 35(6):605–612

    Article  CAS  PubMed  Google Scholar 

  • Pott C, Hoster E, Delfau-Larue MH et al (2010) Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 115(16):3215–3223

    Article  CAS  PubMed  Google Scholar 

  • Pott C, Hoster E, Kehden B, Unterhalt M, Herold M, van der Jagt R, Janssens A, Kneba M, Mayer M, Pocock C, Danesi N, Fingerle-Rowson G, Harbron C, Mundt K, Marcus RE, Hiddemannnn W (2016) Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 GALLIUM study. Blood 128: abstract 623. 2015

    Google Scholar 

  • Rambaldi A, Carlotti E, Oldani E et al (2005) Quantitative PCR of bone marrow BCL2/IgH positive cells at diagnosis predicts treatment response and long-term outcome in Follicular non Hodgkin’s Lymphoma. Blood 105(9):3428–3433

    Article  CAS  PubMed  Google Scholar 

  • Roschewski M, Stetler-Stevenson M, Yuan SM et al (2014) Minimal residual disease: what are the minimum requirements? J Clin Oncol 32(5):475–476

    Article  PubMed  Google Scholar 

  • Roschewski M, Staudt LM, Wilson WH (2016) Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma. Blood 127(25):3127–3133

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ (2018) Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 131(12):1275–1291

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Terwijn M, van Putten WLJ, Kelder A et al (2013) High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol 31(31):3889–3897

    Article  PubMed  Google Scholar 

  • Theunissen P, Mejstrikova E, Sedek L, van der Sluijs-Gelling AJ, Gaipa G, Bartels M, Sobral da Costa E, Kotrová M, Novakova M, Sonneveld E, Buracchi C, Bonaccorso P, Oliveira E, Te Marvelde JG, Szczepanski T, Lhermitte L, Hrusak O, Lecrevisse Q, Grigore GE, Froňková E, Trka J, Brüggemann M, Orfao A, van Dongen JJ, van der Velden VH, EuroFlow Consortium (2017) Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood 129(3):347–357

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Topp MS, Gökbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M, Neumann SA, Horst HA, Raff T, Viardot A, Stelljes M, Schaich M, Köhne-Volland R, Brüggemann M, Ottmann OG, Burmeister T, Baeuerle PA, Nagorsen D, Schmidt M, Einsele H, Riethmüller G, Kneba M, Hoelzer D, Kufer P, Bargou RC (2012) Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120:5185–5187

    Article  CAS  PubMed  Google Scholar 

  • Turajlic S, Swanton C (2016) Metastasis as an evolutionary process. Science 352:169–175

    Article  CAS  PubMed  Google Scholar 

  • Yin JAL, O’Brien MA, Hills RK et al (2012) Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood 120(14):2826–2835

    Article  CAS  PubMed  Google Scholar 

  • Zohren F, Bruns I, Pechtel S, Schroeder T, Fenk R, Czibere A, Maschmeyer G, Kofahl-Krause D, Niederle N, Heil G, Losem C, Welslau M, Brugger W, Germing U, Kronenwett R, Barth J, Rummel MJ, Haas R, Kobbe G (2015) Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy. Blood 126(12):1407–1414

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin II, Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Deutschland

    Monika Brüggemann, Christiane Pott & Thomas Stübig

  2. Prof. emeritus, Klinik für Innere Medizin II, Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Deutschland

    Michael Kneba

  3. Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Deutschland

    Andreas Hochhaus

Authors
  1. Monika Brüggemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christiane Pott
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas Stübig
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Kneba
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andreas Hochhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Kneba .

Editor information

Editors and Affiliations

  1. Abt. Hämatologie und Onkologie, Universitätsklinikum Halle-Wittenberg Klinik und Poliklinik Innere Medizin IV, Halle, Sachsen-Anhalt, Deutschland

    Hans-Joachim Schmoll

Section Editor information

  1. Institut für Pathologie, Universitätsklinikum Carl Gustav Carus, Dresden, Deutschland

    Gustavo Bruno Baretton

  2. Institute of Tumor Biology, UKE, Hamburg, Germany

    Klaus Pantel

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Brüggemann, M., Pott, C., Stübig, T., Kneba, M., Hochhaus, A. (2022). Marker für minimale Resterkrankung: Minimal Residual Disease. In: Schmoll, HJ. (eds) Kompendium Internistische Onkologie . Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-46764-0_153-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-46764-0_153-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-46764-0

  • Online ISBN: 978-3-662-46764-0

  • eBook Packages: Springer Referenz Medizin

Publish with us

Policies and ethics

Search

Navigation